{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:01:28Z","timestamp":1790276488671,"version":"4.1.0"},"reference-count":18,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH author"},{"name":"NIH federal employees"},{"name":"US government"},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Cutaneous skeletal hypophosphatemia syndrome (CSHS) is an ultrarare disorder defined by epidermal and\/or melanocytic nevi, mosaic skeletal dysplasia, and FGF23-mediated hypophosphatemia. As in other FGF23-mediated hypophosphatemia conditions, individuals with CSHS have renal phosphate wasting and inappropriately normal or frankly low 1,25-dihydroxyvitamin D levels with resultant hypophosphatemia leading to rickets and osteomalacia. Conventional therapy for FGF23-mediated hypophosphatemia consists of multiple daily doses of oral phosphate and active vitamin D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Burosumab is a fully human immunoglobulin G1 monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels and skeletal healing. Given its efficacy in tumor-induced osteomalacia and X-linked hypophosphatemic rickets, two related disorders of FGF23-mediated hypophosphatemia, we explored treatment with burosumab in a young adult with CSHS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label, single-patient trial conducted in the clinical research unit of an academic children's hospital, burosumab was administered subcutaneously every 4 weeks for 3\u00a0years. The participant was an 18-year-old woman with CSHS and FGF23-mediated hypophosphatemia. Burosumab was administered subcutaneously every 4 weeks, starting at 0.3\u00a0mg\/kg\/dose and increasing up to 0.9\u2005mg\/kg\/dose. Main outcome measures included change in blood phosphorus levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Burosumab therapy was well tolerated with correction of hypophosphatemia and improvement in other measures including renal phosphate loss, alkaline phosphatase, active vitamin D metabolism, skeletal imaging, pain, physical function, and overall quality of life. Adverse events were manageable, with unclear relationship to burosumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that burosumab may be an effective treatment for CSHS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvag040","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:46:25Z","timestamp":1774529185000},"source":"Crossref","is-referenced-by-count":1,"title":["Burosumab treatment in an adult with FGF23-mediated hypophosphatemia due to cutaneous skeletal hypophosphatemia syndrome"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8827-9883","authenticated-orcid":false,"given":"Laura L","family":"Tosi","sequence":"first","affiliation":[{"name":"Bone Health Program, Division of Orthopaedics & Sports Medicine, Children's National Hospital , Washington, DC 20010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmer N","family":"Rajah","sequence":"additional","affiliation":[{"name":"Bone Health Program, Division of Orthopaedics & Sports Medicine, Children's National Hospital , Washington, DC 20010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin P","family":"Gillies","sequence":"additional","affiliation":[{"name":"Bone Health Program, Division of Orthopaedics & Sports Medicine, Children's National Hospital , Washington, DC 20010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirini","family":"Kim","sequence":"additional","affiliation":[{"name":"Bone Health Program, Division of Orthopaedics & Sports Medicine, Children's National Hospital , Washington, DC 20010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Reid","sequence":"additional","affiliation":[{"name":"Bone Health Program, Division of Orthopaedics & Sports Medicine, Children's National Hospital , Washington, DC 20010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel I","family":"Gafni","sequence":"additional","affiliation":[{"name":"Bone Health Program, Division of Orthopaedics & Sports Medicine, Children's National Hospital , Washington, DC 20010 ,","place":["USA"]},{"name":"National Institute of Dental and Craniofacial Research, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"2","key":"2026032707542476500_bvag040-B1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/ddt429","article-title":"Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia","volume":"23","author":"Lim","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"9","key":"2026032707542476500_bvag040-B2","doi-asserted-by":"crossref","first-page":"e159330","DOI":"10.1172\/JCI159330","article-title":"Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source","volume":"133","author":"Ovejero","year":"2023","journal-title":"J Clin Invest"},{"issue":"12","key":"2026032707542476500_bvag040-B3","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s00198-016-3702-8","article-title":"Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment","volume":"27","author":"Ovejero","year":"2016","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026032707542476500_bvag040-B4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2015.11.012","article-title":"Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy","volume":"75","author":"Lim","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2026032707542476500_bvag040-B5","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1530\/EJE-19-0969","article-title":"DIAGNOSIS OF ENDOCRINE DISEASE: mosaic disorders of FGF23 excess: fibrous dysplasia\/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome","volume":"182","author":"de Castro","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026032707542476500_bvag040-B6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00223-020-00705-3","article-title":"New therapies for hypophosphatemia-related to FGF23 excess","volume":"108","author":"Athonvarangkul","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"2026032707542476500_bvag040-B7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026032707542476500_bvag040-B8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"2026032707542476500_bvag040-B9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"2026032707542476500_bvag040-B10","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2026032707542476500_bvag040-B11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"10189","key":"2026032707542476500_bvag040-B12","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"2026032707542476500_bvag040-B13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"2026032707542476500_bvag040-B14","doi-asserted-by":"crossref","first-page":"101138","DOI":"10.1016\/j.bonr.2021.101138","article-title":"Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: a case report","volume":"15","author":"Khadora","year":"2021","journal-title":"Bone Rep"},{"key":"2026032707542476500_bvag040-B15","doi-asserted-by":"crossref","first-page":"866831","DOI":"10.3389\/fendo.2022.866831","article-title":"A case report: first long-term treatment with burosumab in a patient with cutaneous-skeletal hypophosphatemia syndrome","volume":"13","author":"Merz","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026032707542476500_bvag040-B16","doi-asserted-by":"crossref","first-page":"101605","DOI":"10.1016\/j.bonr.2022.101605","article-title":"A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets","volume":"17","author":"Huynh","year":"2022","journal-title":"Bone Rep"},{"key":"2026032707542476500_bvag040-B17","doi-asserted-by":"crossref","first-page":"101725","DOI":"10.1016\/j.bonr.2023.101725","article-title":"Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome","volume":"20","author":"Abebe","year":"2023","journal-title":"Bone Rep"},{"key":"2026032707542476500_bvag040-B18","doi-asserted-by":"crossref","first-page":"116598","DOI":"10.1016\/j.bone.2022.116598","article-title":"The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome","volume":"166","author":"Sugarman","year":"2023","journal-title":"Bone"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/4\/bvag040\/67592060\/bvag040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/4\/bvag040\/67592060\/bvag040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:54:34Z","timestamp":1774612474000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvag040\/8549976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,6]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvag040","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,6]]},"article-number":"bvag040"}}